EP2288370A1 - Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique - Google Patents

Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique

Info

Publication number
EP2288370A1
EP2288370A1 EP09732932A EP09732932A EP2288370A1 EP 2288370 A1 EP2288370 A1 EP 2288370A1 EP 09732932 A EP09732932 A EP 09732932A EP 09732932 A EP09732932 A EP 09732932A EP 2288370 A1 EP2288370 A1 EP 2288370A1
Authority
EP
European Patent Office
Prior art keywords
group
polysaccharide
acid
implant according
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09732932A
Other languages
German (de)
English (en)
French (fr)
Inventor
Rémi SOULA
Olivier Soula
Gérard Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0854621A external-priority patent/FR2933306B1/fr
Priority claimed from FR0857560A external-priority patent/FR2937863B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Publication of EP2288370A1 publication Critical patent/EP2288370A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Definitions

  • the present invention relates to the field of osteogenic formulations and more particularly to formulations of osteogenic proteins belonging to the family of Bone Morphogenetic Proteins, BMPs.
  • BMPs Bone Morphogenetic Proteins
  • OPs Osteogenic Proteins
  • BMPs are expressed as propeptides which, after post-translational processing, have a length of between 104 and 139 residues. They have a great homology of sequences between them and have similar three-dimensional structures. In particular, they have 6 cysteine residues involved in intramolecular disulfide bonds forming a "cysteine knot" (Scheufler C. 2004 J. Mol Biol 1999, 287, 103, Schlunegger MP, J. Mol Biol 1993, 231, 445). Some of them have a 7 th cysteine also involved in an intermolecular disulfide bridge responsible for dimer formation (Scheufler C. Mol Biol 2004 J. 1999; 287:... 103).
  • BMPs In their active form, BMPs assemble into homodimers or even heterodimers as described by Israel et al. (Israel Dl, Growth Factors, 1996, 13 (3-4), 291). Dimeric BMPs interact with BMPR transmembrane receptors (Mundy et al., Growth Factors, 2004, 22 (4), 233). This recognition is at the origin of a cascade of intracellular signaling involving Smad proteins in particular resulting in the activation or repression of target genes.
  • BMPs with the exception of BMPs 1 and 3, play a direct and indirect role in the differentiation of mesenchymal cells causing their differentiation into osteoblasts (Cheng H., J. Bone and Joint Surgery, 2003, 85A 1544-1552). They also possess chemotaxis properties and induce proliferation and differentiation.
  • recombinant human BMPs and in particular rhBMP-2 and rhBMP-7, have clearly demonstrated an ability to induce bone formation in vivo in humans and have been approved for certain medical applications.
  • recombinant human BMP-2 dibotermin alfa according to the international nonproprietary name, is formulated in products sold under the name Infuse ® in the US and InductOs ® in Europe. This product is prescribed in the fusion of the lumbar vertebrae and bone regeneration of the tibia for so-called non-union fractures.
  • the surgical procedure consists first of all, to soak a collagen sponge with a solution of rhBMP-2, then to place the sponge in a hollow cage, LT Cage, previously implanted between the vertebrae.
  • OP-1 Implant Human recombinant BMP-7, eptotermin alpha according to the international nonproprietary name, has the same therapeutic indications as BMP-2 and is the basis of two products: OP-1 Implant for open fractures of the tibia and OP-1 Putty for the fusion of the lumbar vertebrae.
  • OP-1 Implant consists of a powder containing rhBMP-7 and collagen to be taken up in 0.9% saline solution. The paste obtained is then applied to the fracture during a surgical procedure.
  • OP-1 Putty comes in the form of two powders: one containing rhBMP-7 and collagen, the other carboxymethylcellulose (CMC). During surgery, the CMC solution is reconstituted with 0.9% saline and mixed with rhBMP-7 and collagen. The paste thus obtained is applied to the site to be treated.
  • Patent application US2008 / 014197 discloses an osteoinductive implant consisting of a support (scaffold) containing a mineral ceramic, a solid membrane integrally bonded to the support and an osteogenic agent.
  • the support is preferably a collagen sponge.
  • the mineral ceramic comprises a calcium derivative, preferably a water-insoluble mineral matrix such as biphasic calcium phosphate ([0024], p2).
  • the solid membrane integrally bound to the implant must be impervious so as to limit the entry of surrounding soft tissue cells and also prevent the entry of inflammatory cells ([003O] 1 p 3). The entry of these cells into the implant is described as possibly leading to a reduction in bone growth and treatment failure ([0007], p 1).
  • This invention is focused on adding a membrane to the implant to improve osteogenesis.
  • US2007 / 0254041 discloses a sheet-shaped device containing a demineralized bone matrix (DBM), collagen particles and a physically cross-linked polysaccharide matrix.
  • This implant may also contain an osteogenic substance such as a growth factor.
  • the physically cross-linked polysaccharide serves as a stabilizer for the demineralized bone particles ([0026], p 3).
  • the alginate-based polysaccharide is crosslinked by addition of calcium chloride.
  • the patent application WO96 / 39203 describes an osteogenic and biocompatible composite material with a physical resistance.
  • This osteoinductive material is composed of demineralized bone, osteoinduction can only take place in the presence of demineralized bone, or in the presence of protein extracts of demineralized bone, or in the presence of these two elements according to the authors (lines 2-5, p 2).
  • a calcium salt or a mineral salt is described as possibly being sodium hydroxide, sodium chloride, magnesium chloride or magnesium hydroxide (lines 4-9, p 17).
  • the calcium salt may be a soluble salt or not (lines 20-21, p 17) and is preferably calcium hydroxide.
  • the selection of the hydroxides of different cations, in particular of calcium, to be added is justified by the effect of increasing the pH of the matrix favorable to the increase of collagen synthesis in this environment (lines 7-11, p 15 ).
  • This invention covers the formation of new demineralized bone implants whose physical and osteogenic properties would be improved by increasing the pH of the implant.
  • this new formulation makes it possible to produce the same osteogenic effect with lesser amounts of growth factors.
  • the invention relates to an open implant consisting of an osteogenic composition comprising at least:
  • a soluble salt of at least divalent cation A soluble salt of at least divalent cation
  • An organic support said organic support not comprising a demineralized bone matrix.
  • open implant means an implant having no membrane or envelope capable of limiting or regulating exchanges with the tissues surrounding the implant and substantially homogeneous in its constitution.
  • Demineralized bone matrix is defined as
  • DBM a matrix obtained by acid extraction of autologous bone, leading to the loss of the majority of the mineralized components but to the preservation of collagenic or non-collagenic proteins, including growth factors.
  • Such a demineralized matrix may also be prepared in an inactive form after extraction with chaotropic agents.
  • organic support is meant a support consisting of an organic matrix and / or a hydrogel.
  • organic matrix is meant a matrix consisting of cross-linked hydrogels and / or collagen.
  • the organic matrix is a hydrogel obtained by chemical crosslinking of polymer chains. Interchain covalent bonds defining an organic matrix. Polymers that can be employed for the constitution of an organic matrix are described in Hoffman's review Hydrogels for Biomedical Applications (Ad v. Drug Deliv Rev, 2002, 43, 3-12).
  • the matrix is chosen from the matrices based on purified, sterilized natural collagen.
  • Natural polymers such as collagen are components of the extracellular matrix that promote attachment, migration and cell differentiation. They have the advantage of being extremely biocompatible and are degraded by enzymatic digestion mechanisms.
  • Collagen-based matrices are obtained from fibrillar type I or IV collagen extracted from tendon or beef or pork bone. These collagens are first purified before being crosslinked and then sterilized.
  • the organic supports according to the invention can be used as a mixture to obtain materials which can be in the form of a material with sufficient mechanical properties to be formed or molded or in the form of a "putty" or the collagen or hydrogel plays a role of binder.
  • Mixed materials can also be used, for example a matrix which combines collagen and inorganic particles and which can be in the form of a composite material with reinforced mechanical properties or in the form of a "putty" or the collagen plays a role of binder.
  • Usable inorganic materials include essentially calcium phosphate ceramics such as hydroxyapatite (HA), tricalcium calcium phosphate (TCP), biphasic calcium phosphate (BCP) or amorphous calcium phosphate (ACP) which have as their main interest a chemical composition very close to that of the bone. These materials have good mechanical properties and are immunologically inert. These materials can be in various forms such as powders, aggregates or blocks. These materials have very different degradation rates depending on their compositions and hydroxyapatite is degraded very slowly (several months) while tricalcium calcium phosphate degrades more quickly (several weeks). It is for this purpose that biphasic calcium phosphates have been developed because they have intermediate resorption rates. These inorganic materials are known to be primarily osteoconductive.
  • HA hydroxyapatite
  • TCP tricalcium calcium phosphate
  • BCP biphasic calcium phosphate
  • ACP amorphous calcium phosphate
  • hydrogel means a hydrophilic three-dimensional network of polymer capable of adsorbing a large quantity of water or biological fluids (Peppas et al., Eur J Pharm Biopharm 2000, 50, 27-46). Such a hydrogel consists of physical interactions and is therefore not obtained by chemical crosslinking of the polymer chains.
  • the crosslinked or non-crosslinked hydrogel-forming polymer is selected from the group of synthetic polymers, among which are copolymers of ethylene glycol and lactic acid, copolymers of ethylene glycol and glycolic acid, poly (N-vinyl pyrrolidone), polyvinyl acids, polyacrylamides, polyacrylic acids.
  • the hydrogel-forming polymer is chosen from the group of natural polymers among which hyaluronic acid, keratane, pullulan, pectin, dextran, cellulose and cellulose derivatives, alginic acid , xanthan, carrageenan, chitosan, chondroitin, collagen, gelatin, polylysine, fibrin and their biologically acceptable salts.
  • the natural polymer is chosen from the group of hydrogel-forming polysaccharides, among which hyaluronic acid, aiginic acid, dextran, pectin, cellulose and its derivatives, pullulan, xanthan, carrageenan, chitosan, chondroitin and their biologically acceptable salts.
  • the natural polymer is chosen from the group of hydrogel-forming polysaccharides, among them hyaluronic acid, alginic acid and their biologically acceptable salts.
  • Amphiphilic polysaccharide is understood to mean a polysaccharide chosen from the group of polysaccharides functionalized with hydrophobic derivatives.
  • polysaccharides consist mainly of (1, 4) and / or (1, 3) and / or (1, 2) glycosidic linkages. They can be neutral, that is to say they can not carry acidic or anionic functions and carry acid functions.
  • Trp tryptophan derivatives
  • said tryptophan derivative being grafted or bound to the polysaccharides by coupling with an acid function, said acid function possibly being an acid function of an anionic polysaccharide and / or an acid function carried by a linker R linked to the polysaccharide by a function F said function F resulting from the coupling between the linker R and a function -OH of the neutral or anionic polysaccharide,
  • F being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function
  • - R being a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated comprising one or more heteroatoms, such as O, N and / or S, and having at least one acid function,
  • Trp being a residue of a tryptophan derivative, L or D, produces coupling between the tryptophan amine and the at least one acid carried by the R group and / or an acid carried by the anionic polysaccharide.
  • the polysaccharide predominantly comprising glycoside bonds of the type (1, 4), (1, 3) and / or (1, 2) functionalized with at least one tryptophan derivative may correspond to the following general formula I :
  • the polysaccharide predominantly consisting of (1,4) and / or (1,3) and / or (1,2) glycosidic bonds, F resulting from the coupling between the linker R and an OH function of the neutral or anionic polysaccharide, being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function,
  • R being a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated comprising one or more heteroatoms, such as O, N or / and S, and having at least one acidic function
  • Trp being a residue of a tryptophan derivative, L or D, produces coupling between the amine of the tryptophan derivative and the at least one acid carried by the R group and / or an acid carried by the anionic polysaccharide.
  • n represents the molar fraction of the Rs substituted by Trp and is between 0.05 and 0.7.
  • 0 represents the mole fraction of the acid functions of the polysaccharides substituted with Trp and is between 0.05 and 0.7.
  • j represents the mole fraction of acid functional groups carried by the anionic polysaccharide per saccharide unit and is between 0 and 1
  • (i - + j) represents the mole fraction of acid functions per saccharide unit and is between 0.1 and 2
  • the acid or acids of the R group are cation carboxylates, alkali preferably as Na or K.
  • polysaccharide when the polysaccharide is an anionic polysaccharide, when one or more acid functions of the polysaccharide are not substituted by
  • Trp then they are salified by a cation, alkaline preferably as Na + or K + , said polysaccharides being amphiphilic at neutral pH.
  • F is either an ester, a carbonate, a carbamate or an ether.
  • the polysaccharide consists predominantly of glycoside bonds of the type (1, 4). In one embodiment, the polysaccharide predominantly composed of glycoside bonds of type (1, 4) is selected from the group consisting of pullulan, alginate, hyaluronan, xylan, galacturonan or a cellulose soluble in the water. In one embodiment, the polysaccharide is a pullulan.
  • the polysaccharide is an alginate.
  • the polysaccharide is a hyaluronan.
  • the polysaccharide is a xylan.
  • the polysaccharide is a galacturonan. In one embodiment, the polysaccharide is a water-soluble cellulose.
  • the polysaccharide consists predominantly of glycoside bonds of type (1, 3). In one embodiment, the polysaccharide consisting predominantly of glycoside bonds of type (1, 3) is a curdlane.
  • the polysaccharide consists predominantly of glycoside bonds of type (1, 2). In one embodiment, the polysaccharide consisting predominantly of glycoside bonds of type (1, 2) is an inulin.
  • the polysaccharide consists predominantly of glycoside bonds of type (1, 4) and (1, 3). In one embodiment, the polysaccharide predominantly composed of glycoside bonds of (1,4) and (1,3) type is a glucan.
  • the polysaccharide consists predominantly of (1,4) and (1,3) and (1,2) glycosidic linkages. In one embodiment, the polysaccharide predominantly composed of glycoside bonds of (1,4) and (1,3) and (1,2) type is mannan.
  • the polysaccharide according to the invention is characterized in that the group R is chosen from the following groups:
  • the polysaccharide according to the invention is characterized in that the tryptophan derivative is selected from the group consisting of tryptophan, tryptophanol, tryptophanamide, 2-indole ethylamine and their alkaline cation salts.
  • the polysaccharide according to the invention is characterized in that the tryptophan derivative is chosen from the esters of tryptophan of formula II.
  • E being a group that can be:
  • a linear or branched C1 to C8 alkyl A linear or branched C1 to C8 alkyl.
  • a linear or branched C 6 -C 20 alkylaryl or arylalkyl is A linear or branched C 6 -C 20 alkylaryl or arylalkyl.
  • the polysaccharide may have a degree of polymerization m of between 10 and 10,000.
  • polysaccharides are chosen from the group of dextrans functionalized with hydrophobic amino acids such as tryptophan and tryptophan derivatives as described in application FR 07/02316.
  • the functionalized dextran may correspond to the following general formula III:
  • R being a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated comprising one or more heteroatoms, such as O, N or / and S, and having at least one acid function
  • AA being a hydrophobic amino acid residue, L or D, produces coupling between the amino acid amine and an acid carried by the R group.
  • t represents the mole fraction of substituent F-R- [AA] n per glycoside unit and is between 0.1 and 2
  • p represents the mole fraction of Rs substituted with AA and is between 0.05 and 1.
  • the acid or acids of the R group are cationic carboxylates, preferably alkaline, such as Na + , K + , said dextran being amphiphilic at neutral pH.
  • the alkaline cation is Na + .
  • F is either an ester, a carbonate, a carbamate or an ether.
  • the polysaccharide according to the invention is a carboxymethyl dextran of formula IV.
  • the polysaccharide according to the invention is a monosuccinic ester of dextran of formula V:
  • the polysaccharide according to the invention is characterized in that the group R is chosen from the following groups:
  • the dextran according to the invention is characterized in that the hydrophobic amino acid is chosen from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide and 2-indole ethylamine and their salts. alkaline cation.
  • the dextran according to the invention is characterized in that the tryptophan derivatives are chosen from the tryptophan esters of formula II as defined above.
  • the dextran according to the invention is a tryptophan modified carboxymethyldextran of formula VI:
  • the dextran according to the invention is a monosuccinic ester of dextran modified with tryptophan of formula VII:
  • the dextran according to the invention is characterized in that the hydrophobic amino acid is selected from phenylalanine, leucine, isoleucine and valine and their alcohol, amide or decarboxylated derivatives. In one embodiment, the dextran according to the invention is characterized in that the derivatives of phenylalanine, leucine, isoleucine and valine are chosen from the esters of these amino acids of formula VIII.
  • the dextran according to the invention is characterized in that the hydrophobic amino acid is phenylalanine, and its alcohol, amide or decarboxylated derivatives.
  • Dextran may have a degree of polymerization m of between 10 and 10,000.
  • it has a degree of polymerization m of between 10 and 1000.
  • it has a degree of polymerization m of between 10 and 500.
  • the polysaccharides are chosen from the group of polysaccharides comprising carboxyl functional groups such as those described in application FR 08/05506, at least one of which is substituted by a hydrophobic alcohol derivative, denoted by Ah: hydrophobic alcohol (Ah) being grafted or bound to the anionic polysaccharide by a coupling arm R, said coupling arm being bonded to the anionic polysaccharide by a function F 'said function F' resulting from the coupling between the amine function of the linker R and a carboxyl function of the anionic polysaccharide, and said coupling arm being bonded to the hydrophobic alcohol by a function G resulting from the coupling between a carboxyl, isocyanate, thioacid or alcohol function of the coupling arm and a function of the hydrophobic alcohol, the carboxyl functions of the unsubstituted anionic polysaccharide being in the form of a cation carboxylate, preferably alka
  • G being either an ester, thioester, carbonate or carbamate function
  • R being a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated, optionally comprising one or more heteroatoms, such as O, N or / and S, and having at least one acid function,
  • Ah being a residue of a hydrophobic alcohol, produces coupling between the hydroxyl function of the hydrophobic alcohol and at least one electrophilic function carried by the group R.
  • said polysaccharide having carboxyl functional groups being amphiphilic at neutral pH.
  • polysaccharide having carboxyl functional groups partially substituted by hydrophobic alcohols is chosen from polysaccharides comprising carboxyl functional groups of general formula IX:
  • the carboxyl functional group (s) of the polysaccharide are carboxylates of cation, alkali preferably as Na + or K + .
  • the polysaccharides comprising carboxyl functional groups are polysaccharides naturally carrying carboxyl functional groups and are chosen from the group consisting of alginate, hyaluronan and galacturonan.
  • the polysaccharides comprising carboxyl functional groups are synthetic polysaccharides obtained from polysaccharides naturally having carboxyl functional groups or from neutral polysaccharides on which at least 15 carboxyl functional groups per 100 saccharide units have been grafted with general formula X.
  • the natural polysaccharides being chosen from the group of polysaccharides consisting mainly of (1, 6) and / or (1, 4) and / or (1, 3) and / or (1, 2) glycoside bonds,
  • L being a bond resulting from the coupling between the linker Q and an OH function of the polysaccharide and being either an ester, thioester, carbonate, carbamate or ether function,
  • r represents the mole fraction of the L-Q substituents per saccharide unit of the polysaccharide
  • the polysaccharide being a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated comprising one or more heteroatoms, such as O, N and / or S, and comprising at least one carboxyl functional group, - CO 2 H
  • the polysaccharide consists predominantly of glycoside bonds of (1, 6) type.
  • the polysaccharide consisting predominantly of glycoside bonds of type (1, 6) is dextran.
  • the polysaccharide consists predominantly of glycoside bonds of (1, 4) type.
  • the polysaccharide predominantly composed of glycoside bonds of type (1, 4) is selected from the group consisting of pullulan, alginate, hyaluronan, xylan, galacturonan or a cellulose soluble in the water.
  • the polysaccharide is a pullulan. In one embodiment, the polysaccharide is an alginate.
  • the polysaccharide is a hyaluronan. In one embodiment, the polysaccharide is a xylan. In one embodiment, the polysaccharide is a galacturonan. In one embodiment, the polysaccharide is a water-soluble cellulose.
  • the polysaccharide consists predominantly of glycoside bonds of type (1, 3).
  • the polysaccharide consisting predominantly of glycoside bonds of type (1, 3) is a curdlane.
  • the polysaccharide consists predominantly of glycoside bonds of type (1, 2).
  • the polysaccharide consisting predominantly of glycoside bonds of type (1, 2) is an inulin.
  • the polysaccharide consists predominantly of (1,4) and (1,3) glycosidic linkages.
  • the polysaccharide predominantly composed of glycoside bonds of (1,4) and (1,3) type is a glucan. In one embodiment, the polysaccharide consists predominantly of (1,4) and (1,3) and (1,2) glycosidic linkages.
  • the polysaccharide predominantly composed of glycoside bonds of (1,4) and (1,3) and (1,2) type is mannan.
  • the polysaccharide according to the invention is characterized in that the group Q is chosen from the following groups:
  • r is between 0.1 and 2.
  • r is 0.2 to 1.5.
  • the group R according to the invention is characterized in that it is chosen from amino acids.
  • the amino acids are selected from alpha amino acids.
  • the alpha amino acids are selected from alpha natural amino acids.
  • the natural alpha amino acids are chosen from leucine, alanine, iso-leucine, glycine, phenylalanine, tryptophan and valine.
  • the hydrophobic alcohol is selected from fatty alcohols.
  • the hydrophobic alcohol is chosen from alcohols consisting of an unsaturated or saturated alkyl chain comprising from 4 to 18 carbons.
  • the fatty alcohol is selected from meristyl, cetyl, stearyl, cetearyl, butyl, oleyl and lanolin.
  • the hydrophobic alcohol is selected from cholesterol derivatives.
  • the cholesterol derivative is cholesterol
  • the hydrophobic alcohol Ah is selected from tocopherols.
  • the tocopherol is alpha tocopherol.
  • alpha tocopherol is the racemic alpha tocopherol.
  • the hydrophobic alcohol is selected from alcohols bearing aryl groups.
  • the aryl group bearing alcohol is selected from benzyl alcohol, phenethyl alcohol.
  • the polysaccharide may have a degree of polymerization m of between 10 and 10,000.
  • it has a degree of polymerization m of between 10 and 1000.
  • it has a degree of polymerization m of between 10 and 500.
  • said composition is in the form of lyophilisate.
  • the at least one divalent cation soluble salt is a divalent cation soluble salt selected from calcium, magnesium or zinc cations.
  • the at least one divalent cation soluble salt is a soluble calcium salt.
  • soluble salt of at least divalent cation means a salt whose solubility is equal to or greater than 5 mg / ml, preferably 10 mg / ml, preferably 20 mg / ml.
  • the divalent cation soluble salt is a calcium salt whose counterion is selected from chloride, D-gluconate, formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the divalent cation soluble salt is a magnesium salt whose counterion is selected from chloride, D-gluconate, formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the divalent cation soluble salt is a zinc salt whose counterion is selected from chloride, D-gluconate, formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the divalent cation soluble salt is calcium chloride.
  • the soluble cation salt is a soluble multivalent cation salt.
  • multivalent cations are meant species carrying more than two positive charges such as iron, aluminum, cationic polymers such as polylysine, spermine, protamine, fibrin.
  • cationic polymers such as polylysine, spermine, protamine, fibrin.
  • osteogenic growth factor or BMP alone or in combination is meant a BMP selected from the group of therapeutically active BMPs (Bone Morphogenetic Proteins).
  • the osteogenic proteins are selected from the group consisting of BMP-2 (Dibotermin-alpha), BMP-4, BMP-7 (Eptotermin-alpha), BMP-14 and GDF-5.
  • the osteogenic protein is BMP-2 (Dibotermin-alpha). In one embodiment, the osteogenic protein is GDF-5.
  • the BMPs used are recombinant human BMPs, obtained according to the techniques known to those skilled in the art or purchased from suppliers such as, for example, Research Diagnostic Inc. (USA).
  • the hydrogel can be prepared just prior to implantation.
  • the hydrogel may be prepared and stored in a pre-filled syringe for subsequent implantation.
  • the hydrogel may be prepared by rehydrating a lyophilisate just prior to implantation or implanted in dehydrated form.
  • Lyophilization is a water sublimation technique allowing dehydration of the composition. This technique is commonly used for protein storage and stabilization.
  • a lyophilizate is very rapid and makes it possible to easily obtain a ready-to-use formulation, said formulation being able to be rehydrated before implantation or implanted in its dehydrated form, the rehydration then taking place, after implantation, by contact with biological fluids.
  • osteogenic growth factors it is possible to add other proteins and in particular angiogenic growth factors such as PDGF 1, VEGF or FGF.
  • the invention therefore relates to a composition according to the invention characterized in that it further comprises angiogenic growth factors selected from the group consisting of PDGF, VEGF or FGF.
  • the osteogenic compositions according to the invention are used by implantation for example to fill bone defects, to perform vertebral fusions or maxillofacial repairs or for the treatment of the absence of fracture consolidation (non-union).
  • the size of the matrix and the amount of osteogenic growth factor are a function of the volume of the site to be filled.
  • the anionic polysaccharide solutions have concentrations of between 0.1 mg / ml and 100 mg / ml, preferably 1 mg / ml at 75 mg / ml, more preferably between 5 and 50 mg / ml.
  • the osteogenic growth factor doses will be between 0.05 mg to 8 mg, preferably between 0.1 mg and 4 mg, more preferably between 0.1 mg and 2 mg. , while the doses currently accepted in the literature are between 8 and 12 mg.
  • the doses of angiogenic growth factor will be between 0.05 mg and 8 mg, preferably between 0.1 mg and 4 mg, more preferably between 0.1 mg and 2 mg. mg.
  • doses administered will be less than 1 mg.
  • the divalent cation solutions have concentrations of between 0.01 and 1 M, preferably between 0.05 and 0.2 M.
  • the anionic polysaccharide solutions have concentrations of between 0.1 mg / ml and 100 mg / ml, preferably 1 mg / ml at 75 mg / ml, more preferably between 5 and 50 mg / ml.
  • the invention also relates to the process for preparing an implant according to the invention which comprises at least the following steps: a) a solution comprising an osteogenic growth factor / anionic polysaccharide complex and an organic matrix and or a hydrogel, b) adding the solution containing the complex to the organic matrix and / or the hydrogel, and optionally mixing the mixture, c) adding to the implant obtained in b) a solution of a soluble salt of at least divalent cation, d) optionally performs the lyophilization of the implant obtained in step c).
  • the invention also relates to the process for preparing an implant according to the invention which comprises at least the following steps:
  • the organic matrix is a matrix consisting of crosslinked hydrogels and / or collagen. In one embodiment, the matrix is chosen from the matrices based on purified natural collagen, sterilized, preferably crosslinked.
  • the crosslinked or non-crosslinked hydrogel-forming polymer is selected from the group of synthetic polymers, among which are copolymers of ethylene glycol and lactic acid, copolymers of ethylene glycol and glycolic acid, poly (N-vinyl pyrrolidone), polyvinyl acids, polyacrylamides, polyacrylic acids.
  • the crosslinked or non-crosslinked hydrogel-forming polymer is chosen from the group of natural polymers, among which hyaluronic acid, keratane, pectin, dextran, cellulose and cellulose derivatives, alginic acid, xanthan, carrageenan, chitosan, chondroitin, collagen, gelatin, polylysine, fibrin and their biologically acceptable salts.
  • the natural polymer is chosen from the group of polysaccharides forming hydrogels, among which hyaluronic acid, alginic acid, dextran, pectin, cellulose and its derivatives, pullulan, xanthan, carrageenan, chitosan, chondroitin and their biologically acceptable salts.
  • the natural polymer is chosen from the group of hydrogel-forming polysaccharides, among them hyaluronic acid, alginic acid and their biologically acceptable salts.
  • the at least divalent cation soluble salt solution is a divalent cation solution.
  • the soluble salts of divalent cation are calcium salts whose counterion is chosen from among chloride, D-gluconate, formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the divalent cation soluble salt is calcium chloride.
  • the soluble salts of divalent cation are magnesium salts whose counterion is chosen from chloride,
  • D-gluconate formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the soluble salts of divalent cation are zinc salts whose counterion is chosen from chloride, D-gluconate, formate, D-saccharate, acetate, L-lactate, glutamate, aspartate, propionate, fumarate, sorbate, bicarbonate, bromide or ascorbate.
  • the at least divalent cation soluble salt solution is a multivalent cation solution.
  • the multivalent cations are selected from the group consisting of multivalent cations of iron, aluminum, cationic polymers such as polylysine, spermine, protamine, fibrin.
  • step a a solution of a non-osteogenic growth factor is also available.
  • the invention also relates to the use of the composition according to the invention as a bone implant.
  • said composition may be used in combination with a prosthetic device of the type of vertebral prosthesis or vertebral fusion cage.
  • Example 1 Preparation of sodium dextranmethylcarboxylate modified with the sodium salt of L-tryptophan
  • Polymer 1 is a sodium dextranmethylcarboxylate modified with the sodium salt of L-tryptophan obtained from a dextran with a weight average molar mass of 40 kg / mol, ie a degree of polymerization of 154 (Pharmacosmos) according to the process. described in the patent application FR07.02316.
  • the molar fraction of tryptophan-modified sodium methylcarboxylates, p in formula III is 0.36.
  • Polymer 2 is a sodium dextranethyl carboxylate modified with the ethyl ester of L-tryptophan obtained from a dextran with a weight average molar mass of 40 kg / mol, ie a degree of polymerization of 154 (Pharmacosmos) according to the process. described in the patent application FR07.02316.
  • the mole fraction of sodium methylcarboxylates, whether or not modified with the ethyl ester of tryptophan, is t in formula III, is 1.07.
  • the molar fraction of tryptophan ethyl ester-modified sodium methylcarboxylates, p in formula III is 0.49.
  • Polymer 3 is a sodium dextranethyl carboxylate modified with the decyl ester of L-glycine obtained from a dextran with a weight average molar mass of 40 kg / mol, ie a degree of polymerization of 154.
  • Polymer 4 is a sodium dextranethyl carboxylate modified with the octanoic ester of L-phenylalanine obtained from a dextran with a weight average molar mass of 40 kg / mol, ie a degree of polymerization of 154 (Pharmacosmos) according to US Pat. process described in the patent application FR08.05506.
  • the mole fraction of sodium methylcarboxylates, modified or not with the octanoic ester of L-phenylalanine, ie r in formula X is 1.07.
  • the molar fraction of octanoic ester-modified sodium methylcarboxylates of L-phenylalanine, q in formula IX is 0.08.
  • Formulation 1 50 ⁇ l of a solution of rhGDF-5 at 2.0 mg / ml in 5 mM PHCI are mixed with 50 ⁇ l of a solution of Polymer 3 at 61.1 mg / ml.
  • the polymer solution is buffered with 20 mM phosphate (pH 7.2).
  • the GDF-5 / Polymer 3 complex solution is at pH 6.4 and contains 10 mM phosphate.
  • the molar ratio GDF-5 / Polymer 3 is 1/20.
  • This solution is finally filtered on 0.22 ⁇ m.
  • the final solution is clear and is characterized by Dynamic Diffusion of Light. Most of the objects present measure less than 10 nm.
  • Formulation 2 679 ⁇ l of a solution of rhGDF-5 at 3.7 mg / ml in 10 mM HCl are mixed with 1821 ⁇ l of a solution of Polymer 4 at 42.3 mg / ml (pH 7 , 3).
  • the GDF-5 / Polymer 4 complex solution is at pH 6.5 and contains 1 mg / ml of GDF-5 and 30.8 mg / ml of Polymer 4.
  • the molar ratio of GDF-5 / Polymer 4 is 1/20.
  • This solution is finally filtered on 0.22 ⁇ m.
  • the final solution is clear and is characterized by Dynamic Diffusion of Light. Most of the objects present measure less than 10 nm.
  • Example 7 Preparation of collagen sponge implants / rhBMP-2
  • Implant 1 40 ⁇ l of a solution of rhBMP-2 at 0.05 mg / ml are introduced sterilely in a sterile 200 mm3 crosslinked collagen sponge of the Helistat type (Integra LifeSciences, Plainsboro, New Jersey). The solution is allowed to incubate for 30 minutes in the collagen sponge before use.
  • the dose of BMP-2 is 2 ⁇ g.
  • Implant 2 It is prepared as implant 1 with 40 ⁇ l of a solution of rhBMP-2 at 0.5 mg / ml. The dose of BMP-2 is 20 ⁇ g.
  • Formulation 3 50 ⁇ l of a RhBMP-2 solution at 0.15 mg / ml is mixed with 100 ⁇ l of a 37.5 mg / ml solution of Polymer 1.
  • the solutions of rhBMP-2 and Polymer 1 are buffered at pH 7.4. This solution is incubated for two hours at 40 ° C. and sterile filtered through 0.22 ⁇ m.
  • Formulation 4 It is prepared as Formulation 3 by mixing 50 ⁇ l of a solution of rhBMP-2 at 1.5 mg / ml with 100 ⁇ l of a solution of Polymer 1 at 37.5 mg / ml.
  • Implant 3 40 ⁇ l of Formulation 4 are introduced into a sterile 200 mm 3 crosslinked collagen sponge of Helistat type (Integra LifeSciences, Plainsboro, New Jersey). The solution is incubated for 30 minutes in the collagen sponge before adding 100 ⁇ l of a solution of calcium chloride at a concentration of 18.3 mg / ml. After 15 minutes, the sponge is ready for use. The dose of BMP-2 is 20 ⁇ g.
  • EXAMPLE 10 Preparation of Implants Collagen Sponge / BMP-2 Complex / Polymer 1 in the Presence of Calcium Chloride, Freeze Dried
  • Implant 4 40 ⁇ l of Formulation 3 are introduced into a sterile 200 mm 3 crosslinked collagen sponge of the Helistat type (Integra LifeSciences, Plainsboro, New Jersey). The solution is incubated for 30 minutes in the collagen sponge before adding 100 ⁇ l of a solution of calcium chloride at a concentration of 18.3 mg / ml. The sponge is then frozen and sterilized lyophilized. The dose of BMP-2 is 2 ⁇ g.
  • Implant 5 II is prepared as implant 4 with 40 ⁇ l of Formulation 4.
  • the dose of BMP-2 is 20 ⁇ g.
  • the objective of this study is to demonstrate the osteoinductive power of different formulations in a model of ectopic bone formation in rats.
  • Male rats of 150 to 250 g Male rats of 150 to 250 g (Sprague Dawley OFA - SD, Charles River Laboratories France, B.P. 109, 69592 ArbresIe) are used for this study.
  • Analgesic treatment (buprenorphine, Temgesic ® , Pfizer, France) is given before surgery.
  • the rats are anesthetized by inhalation of a mixture of O2 isoflurane (1-4%).
  • the fur is removed by shaving over a wide dorsal area.
  • the skin of this dorsal zone is disinfected with a solution of povidone iodine (Vetedine ® solution, Vetoquinol, France).
  • Paravertebral incisions of about 1 cm are made to clear the left and right paravertebral dorsal muscles. Access to the muscles is performed by transfacial incision. Each of the implants is placed in a pocket in such a way that no compression on them can be exerted. Four implants are implanted per rat (two implants per site). The opening of the implants is then sutured using a polypropylene wire (Prolene 4/0, Ethicon, France). The skin is closed with a non-absorbable suture. The rats are then returned to their respective cages and kept under observation during their recovery. At 21 days, the animals are anesthetized with an injection of tiletamine-zolazepam (ZOLETIL ® 25-50 mg / kg, IM, Virbac, France).
  • the animals are then euthanized by injecting a dose of pentobarbital (DOLETHAL ®, VÉTOQUINOL, France).
  • DOLETHAL ® pentobarbital
  • VÉTOQUINOL pentobarbital
  • a macroscopic observation of each site is then carried out, any sign of local intolerance (inflammation, necrosis, haemorrhage) and the presence of bone and / or cartilage tissue is recorded and scored according to the following scale: 0: absence, 1: low, 2: moderate, 3: marked, 4: important.
  • Each of the implants is removed from its implantation site and macroscopic photographs are taken. The size and weight of the implants are then determined. Each implant is then stored in a 10% buffered formalin solution.
  • This in vivo experiment measures the osteoinductive effect of BMP-2 by placing the implant in a muscle of the back of a rat. This non-osseous site is said to be ectopic.
  • a dose of 2 ⁇ g of BMP-2 in a collagen sponge (Implant 1) does not have sufficient osteoinductive power to be able to find the collagen implants after 21 days.
  • the BMP-2 / Polymer 1 (Implant 3) complex in the presence of CaCl 2 in solution in the collagen sponge makes it possible to increase the osteogenic activity of the BMP. -2.
  • the average mass of the implants 3 is about 3 times greater than that of the implants.
  • Lyophilization makes it possible to amplify this increase in osteogenic activity since the average mass of the implants containing 20 ⁇ g of BMP-2 in the form of a complex with Polymer 1 in the presence of freeze-dried CaCb in the collagen sponge (implant 5) is two greater than that of implants in which the BMP-2 / Polymer 1 complex in the presence of CaCl 2 is in solution (implant 3).
  • the BMP-2 complex in the presence of freeze-dried CaCl 2 in the collagen sponge (Implant 4) makes it possible to generate ossified implants with a mass 2 times greater with a bone score equivalent to those with the BMP-2 alone.
  • This new formulation makes it possible to strongly reduce the doses of BMP-2 to be administered while maintaining the osteogenic activity of this protein.
  • Example 12 Preparation of formulations containing the rhBMP-2 / Polymer 1 complex
  • Formulation 5 552 ⁇ l of a solution of rhBMP-2 at 1.35 mg / ml are mixed with 619 ⁇ l of a polymer solution 1 at 60.0 mg / ml.
  • the volume of formulation 5 is completed at 1300 ⁇ l by addition of sterile water. This solution is incubated for two hours at 4 ° C. and sterile filtered through 0.22 ⁇ m.
  • the concentration of rhBMP-2 in formulation 5 is 0.571 mg / ml and that in polymer 1 is 28.6 mg / ml.
  • Formulation 6 It is prepared as Formulation 5 by mixing 175 ⁇ l of a solution of rhBMP-2 at 1.47 mg / ml with 1224 ⁇ l of a solution of polymer 1 at 60.0 mg / ml. The volume of formulation 6 is completed at 1800 ⁇ l by addition of sterile water. The concentration of rhBMP-2 in formulation 6 is 0.14 mg / ml and that in polymer 1 is 40.8 mg / ml.
  • Formulation 7 It is prepared as Formulation 5 by mixing 26.5 ⁇ l of a solution of rhBMP-2 at 1.46 mg / ml at 321.7 ⁇ l of a solution of polymer 1 at 60.0 mg / ml . The formulation volume is completed at
  • rhBMP-2 in formulation 7 is 0.05 mg / ml and that in polymer 1 is 25 mg / ml.
  • Gel 2 1230 ⁇ l of Formulation 5 are transferred to a sterile 10 ml syringe. 5.8 ml of 4% sodium hyaluronate gel 1 containing calcium chloride at a concentration of 13.1 mg / ml are transferred into a sterile 10 ml syringe.
  • the formulation solution 5 is added to the gel 1 by coupling the two syringes and the gel obtained is homogenized by several passages from one syringe to the other.
  • the opaque gel obtained is transferred into a 50 ml Falcon.
  • the concentration of rhBMP-2 in gel 2 is 0.10 mg / ml and that in polymer 1 is 5.0 mg / ml.
  • Gel 4 This gel is prepared using 772 ⁇ l of formulation 7 and
  • rhBMP-2 implanted 100 ⁇ l of the gel 4 are injected per implantation site.
  • the dose of rhBMP-2 implanted is 2 ⁇ g.
  • Example 17 Preparation of a Collagen Implant Containing a Sodium Alginate Gel Containing the RhBMP-2 / Polymer 1 Complex and Calcium Chloride
  • Implant 6 The gel 5 is prepared using 645 .mu.l of formulation 7 and 323 .mu.l of 40 mg / ml sodium alginate gel. 60 ⁇ l of the sodium alginate gel containing the rhBMP-2 / Polymer 1 complex are added to a Helistat type sterile 200 mm 3 cross-linked collagen sponge (Integra LifeSciences, Plainsboro, New Jersey). 40 ⁇ l of a solution of calcium chloride 45.5 mg / ml are also added to this sponge. After 30 minutes of contact time, the sponge is then frozen and lyophilized. This sponge can be directly implanted in the rat. The dose of rhBMP-2 in implant 1 is 2 ⁇ g, that of Polymer 1 is 1 mg.
  • the osteoinductive power is evaluated according to the protocol described in Example 11.
  • a dose of 2 ⁇ g of rhBMP-2 in a collagen sponge (Implant 1) does not have sufficient osteoinductive power to allow explants to be found after 21 days.
  • Plant 2 leads to obtaining ossified explants of 38 mg average mass after 21 days.
  • the sodium hyaluronate gel containing the rhBMP-2 / Polymer 1 (Gel 2) complex in the presence of calcium chloride makes it possible to increase the osteogenic activity of rhBMP-2.
  • the average mass of the explants obtained with the gel 2 is approximately 6 times greater than that of the explants obtained with the collagen implants containing 20 ⁇ g of rhBMP-2 alone (Implant 8).
  • the rhBMP-2 / Polymer 1 complex in the presence of CaCl 2 in the sodium hyaluronate gel (Gel 3) makes it possible to generate ossified explants of mass 9 times higher with a bone score equivalent to explants obtained with collagen implants containing 20 ⁇ g of rhBMP-2 alone (Implant 8).
  • This new formulation makes it possible to strongly reduce the doses of BMP-2 while maintaining the osteogenic activity of this protein.
  • rhBMP-.2 / Polymer 1 in a sodium alginate gel containing calcium chloride makes it possible to generate ossified explants with a mass slightly greater than those obtained. with collagen implants containing 20 ⁇ g of rhBMP-2 alone (Implant 8).
  • This new formulation makes it possible to strongly reduce rhBMP-2 doses while maintaining the osteogenic activity of this protein.
  • the alginate gel containing the rhBMP-2 / Polymer 1 complex can also be deposited in a collagen sponge which serves as a support for the growth of bone cells.
  • 2 ⁇ g of rhBMP-2 (Implant 6) makes it possible to obtain ossified explants with a mass greater than those obtained with collagen implants containing 20 ⁇ g of rhBMP-2 alone (Implant 8).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP09732932A 2008-04-14 2009-04-14 Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique Withdrawn EP2288370A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7113108P 2008-04-14 2008-04-14
US12901208P 2008-05-30 2008-05-30
FR0854621A FR2933306B1 (fr) 2008-07-07 2008-07-07 Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et une matrice organique
US12961608P 2008-07-08 2008-07-08
US19321608P 2008-11-06 2008-11-06
FR0857560A FR2937863B1 (fr) 2008-11-06 2008-11-06 Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et un gel
PCT/IB2009/005235 WO2009127940A1 (fr) 2008-04-14 2009-04-14 Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique

Publications (1)

Publication Number Publication Date
EP2288370A1 true EP2288370A1 (fr) 2011-03-02

Family

ID=40791051

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09732932A Withdrawn EP2288370A1 (fr) 2008-04-14 2009-04-14 Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique

Country Status (12)

Country Link
US (2) US20090291114A1 (https=)
EP (1) EP2288370A1 (https=)
JP (1) JP2011519292A (https=)
KR (1) KR20110014588A (https=)
CN (1) CN102065882A (https=)
AU (1) AU2009237414A1 (https=)
BR (1) BRPI0906553A2 (https=)
CA (1) CA2720203A1 (https=)
IL (1) IL208139A0 (https=)
MX (1) MX2010011267A (https=)
WO (1) WO2009127940A1 (https=)
ZA (1) ZA201006627B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948573B1 (fr) * 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
FR2975099A1 (fr) * 2011-05-10 2012-11-16 Adocia Polysaccharides a degre de fonctionnalisation modulable
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
FR2980796B1 (fr) * 2011-09-30 2014-07-04 Adocia Oligosaccharides fonctionnalises
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2952375A1 (fr) 2009-11-10 2011-05-13 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par esterification par un derive d'alcool hydrophobe
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
WO2011098962A2 (fr) * 2010-02-09 2011-08-18 Adocia Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
WO2012153071A2 (fr) * 2011-05-10 2012-11-15 Adocia Polysaccharides à degré de fonctionnalisation modulable
WO2012153070A1 (fr) * 2011-05-10 2012-11-15 Adocia Oligosaccharides fonctionnalisés
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
KR102000041B1 (ko) 2011-12-29 2019-07-16 엘지디스플레이 주식회사 발광표시장치 및 그 구동방법
KR101364704B1 (ko) * 2012-06-12 2014-02-20 순천향대학교 산학협력단 골 재생을 위한 다공성 하이드로젤 지지체의 제조방법
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
KR101429857B1 (ko) * 2013-06-19 2014-08-13 순천향대학교 산학협력단 골 지혈작용을 위한 복합이중층 섬유매트의 제조방법
NZ721597A (en) * 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
WO2016127253A1 (en) * 2015-02-09 2016-08-18 Spatafora Michael Method and system for enhancing the activity of bone morphogenetic proteins
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
CN108690205A (zh) * 2018-05-28 2018-10-23 深圳市第二人民医院 一种ⅱ型胶原和聚丙烯酰胺复合水凝胶及其制备和应用
CN110368519B (zh) * 2019-08-26 2021-09-21 浙江瑞谷生物科技有限公司 一种基于贻贝粘蛋白的骨科粘合剂
WO2022216691A1 (en) * 2021-04-06 2022-10-13 Boston Scientific Scimed Inc. Therapeutic hydrogels
CN113563493B (zh) * 2021-07-01 2022-06-24 蚌埠医学院 疏水化多糖及其制备方法与应用
CN113662961B (zh) * 2021-07-19 2023-05-12 上海市第十人民医院 一种可捕获镁离子的微流控水凝胶微球及制备方法与应用
CN117757705B (zh) * 2023-04-28 2024-12-20 元素驱动(杭州)生物科技有限公司 可实现支链氨基酸联产的基因工程菌株的构建及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US20040132653A1 (en) * 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
FR2781485B1 (fr) * 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
AU3556400A (en) * 1999-03-17 2000-10-04 Novartis Ag Pharmaceutical compositions
PL351948A1 (en) * 1999-06-04 2003-07-14 Alza Corp Implantable gel compositions and method of making thereof
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
US7033603B2 (en) * 1999-08-06 2006-04-25 Board Of Regents The University Of Texas Drug releasing biodegradable fiber for delivery of therapeutics
US20050244393A1 (en) * 1999-12-22 2005-11-03 Henogen S.A. Sealant or tissue generating product
BR0310087A (pt) * 2002-05-17 2005-08-16 Wyeth Corp Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ES2380340T3 (es) * 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
US8691273B2 (en) * 2005-07-21 2014-04-08 Lisopharm Ag Method for producing hydroxyapatite particles
JP2007037378A (ja) * 2005-07-29 2007-02-08 Pioneer Electronic Corp スイッチング電源の停電検出回路
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
US20070178159A1 (en) * 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
US20070184087A1 (en) * 2006-02-06 2007-08-09 Bioform Medical, Inc. Polysaccharide compositions for use in tissue augmentation
JP2009532552A (ja) * 2006-04-07 2009-09-10 アドシア 二官能化された多糖類
US20080147197A1 (en) * 2006-12-14 2008-06-19 Mckay William F Biodegradable osteogenic porous biomedical implant with impermeable membrane
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009127940A1 *

Also Published As

Publication number Publication date
CN102065882A (zh) 2011-05-18
JP2011519292A (ja) 2011-07-07
MX2010011267A (es) 2010-12-21
CA2720203A1 (fr) 2009-10-22
IL208139A0 (en) 2010-12-30
US20110159068A1 (en) 2011-06-30
WO2009127940A1 (fr) 2009-10-22
BRPI0906553A2 (pt) 2015-07-07
ZA201006627B (en) 2013-02-27
US20090291114A1 (en) 2009-11-26
KR20110014588A (ko) 2011-02-11
AU2009237414A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
EP2288370A1 (fr) Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique
CA2744150A1 (fr) Nouvelle forme d'administration de complexes de proteines osteogeniques
Gao et al. Preparation and biomedical application of injectable hydrogels
EP2178565A1 (fr) COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs
JP5539727B2 (ja) ヒドロゲルを形成する新規な注入可能なキトサン混合物
BR112013012772B1 (pt) Preparação e/ou formulação de proteínas reticuladas com polissacarídeos
FR2933304A1 (fr) Composition synergique osteogenique
FR2948572A1 (fr) Nouvelle forme d'administration de proteines osteogeniques
WO2007028244A1 (fr) Polymeres biodegradables modifies, leur preparation et leur usage pour la fabrication de biomateriaux et de pansements
Kumar et al. Chitosan as a biomedical material: Properties and applications
EP2288371A1 (fr) Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un support organique
JP2024540178A (ja) 修飾アルギン酸塩、ならびにその製造方法および使用方法
Din et al. Temperature and pH-sensitive chitosan-collagen hydrogels for antimicrobial and wound healing applications
FR2933306A1 (fr) Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et une matrice organique
FR2937863A1 (fr) Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et un gel
Cassano et al. Polysaccharides and proteins-based hydrogels for tissue engineering applications
US20080118542A1 (en) Growth Factor Composition
FR2944447A1 (fr) Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un gel
US20200222577A1 (en) Biomaterials comprising gelatin derived from cold-adapted aquatic species
CA2620633A1 (fr) Polymeres biodegradables modifies, leur preparation et leur usage pour la fabrication de biomateriaux et de pansements
FR2933305A1 (fr) Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un matrice organique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20130918